Abstract：
OBJECTIVE: Childhood epilepsy with centrotemporal spikes (CECTS) is known as age-limited focal epilepsy syndrome in childhood. Lacosamide is a third-generation antiepileptic drug. This study aimed to evaluate the efficacy of lacosamide monotherapy for the treatment of CECTS.
METHODS: We enrolled 18 patients (6 girls and 12 boys) who met the following criteria: 1) the age of onset of the seizures was between 3 and 13 years of age; 2) showing at least hemifacial and/or oropharyngeal seizures; 3) interictal discharges in central and/or middle temporal electrodes; 4) no intellectual disability; 5) treatment duration of lacosamide monotherapy over 6 months. We retrospectively collected and analyzed clinical data and treatment information. We evaluated the seizure occurrences during 0-3, 4-6, and 7-12 months from the treatment initiation and the last 6 months of the follow-up. We also evaluated the outcomes as seizure-free if the patients developed no seizures both over 6 months and 3 times of pretreatment mean seizure interval at the last follow-up.
RESULTS: Of the patients, 39%, 67% and 72% were seizure-free during 0-3, 4-6, and 7-12 months from treatment initiation, respectively. Finally, 83% of the patients achieved seizure freedom. Seizure freedom was achieved in 72% during the first 4 months of treatment. All patients continued lacosamide monotherapy during the study, although four patients showed transient fatigue or somnolence.
CONCLUSIONS: Lacosamide showed good efficacy for controlling seizures with fewer adverse effects, and therefore may be a good candidate as a first-line medication for the treatment of new-onset CECTS.
METHODS: We enrolled 18 patients (6 girls and 12 boys) who met the following criteria: 1) the age of onset of the seizures was between 3 and 13 years of age; 2) showing at least hemifacial and/or oropharyngeal seizures; 3) interictal discharges in central and/or middle temporal electrodes; 4) no intellectual disability; 5) treatment duration of lacosamide monotherapy over 6 months. We retrospectively collected and analyzed clinical data and treatment information. We evaluated the seizure occurrences during 0-3, 4-6, and 7-12 months from the treatment initiation and the last 6 months of the follow-up. We also evaluated the outcomes as seizure-free if the patients developed no seizures both over 6 months and 3 times of pretreatment mean seizure interval at the last follow-up.
RESULTS: Of the patients, 39%, 67% and 72% were seizure-free during 0-3, 4-6, and 7-12 months from treatment initiation, respectively. Finally, 83% of the patients achieved seizure freedom. Seizure freedom was achieved in 72% during the first 4 months of treatment. All patients continued lacosamide monotherapy during the study, although four patients showed transient fatigue or somnolence.
CONCLUSIONS: Lacosamide showed good efficacy for controlling seizures with fewer adverse effects, and therefore may be a good candidate as a first-line medication for the treatment of new-onset CECTS.
摘要：
目的：儿童癫痫伴中央颞部棘波（CECTS）被称为儿童年龄限制局灶性癫痫综合征。拉科沙胺是第三代抗癫痫药物。本研究旨在评估拉科沙胺单药治疗CECTS的疗效。
方法：我们招募了18名符合以下标准的患者（6名女孩和12名男孩）：1）癫痫发作的年龄在3至13岁之间；2）至少表现出半面和/或口咽部癫痫发作；3）中央和/或颞中电极的发作间放电；4）无智力障碍；5）拉科沙胺单药治疗持续时间超过6个月。我们回顾性收集和分析临床资料和治疗信息。我们评估了从治疗开始到最后6个月的0-3、4-6和7-12个月的癫痫发作发生情况。如果患者在最后一次随访中在6个月内没有癫痫发作，并且是治疗前平均癫痫发作间隔的3倍，我们还评估了无癫痫发作的结果。
结果：在患者中，39%,67%和72%在治疗开始后的0-3、4-6和7-12个月内无癫痫发作，分别。最后,83%的患者获得了自在的癫痫发作。在治疗的前4个月中，癫痫发作的自由度达到了72％。所有患者在研究期间继续进行拉考沙胺单药治疗，尽管有4例患者表现出短暂的疲劳或嗜睡。
结论：拉科沙胺对控制癫痫发作具有良好的疗效，不良反应较少，因此可能是治疗新发CECTS的一线药物的良好候选药物。
方法：我们招募了18名符合以下标准的患者（6名女孩和12名男孩）：1）癫痫发作的年龄在3至13岁之间；2）至少表现出半面和/或口咽部癫痫发作；3）中央和/或颞中电极的发作间放电；4）无智力障碍；5）拉科沙胺单药治疗持续时间超过6个月。我们回顾性收集和分析临床资料和治疗信息。我们评估了从治疗开始到最后6个月的0-3、4-6和7-12个月的癫痫发作发生情况。如果患者在最后一次随访中在6个月内没有癫痫发作，并且是治疗前平均癫痫发作间隔的3倍，我们还评估了无癫痫发作的结果。
结果：在患者中，39%,67%和72%在治疗开始后的0-3、4-6和7-12个月内无癫痫发作，分别。最后,83%的患者获得了自在的癫痫发作。在治疗的前4个月中，癫痫发作的自由度达到了72％。所有患者在研究期间继续进行拉考沙胺单药治疗，尽管有4例患者表现出短暂的疲劳或嗜睡。
结论：拉科沙胺对控制癫痫发作具有良好的疗效，不良反应较少，因此可能是治疗新发CECTS的一线药物的良好候选药物。
